Specific Clinical Risk Factors: GI Problems in People with Developmental Disabilities
Specific Clinical Risk Factors: GI Problems in People with Developmental Disabilities
Dysphagia, esophageal disorders & GE reflux OPENING COMMENTS: Don’t confuse “usual” with “normal” Don’t ignore the signs that a problem exists (“I told ya and I told ya”) It’s important to be proactive (anticipate) Kitchen to bathroom DYSPHAGIA
• difficulty swallowing (difficulty in passage of food, solid or liquid, from the
• inability to safely take medications orally
ESOPHAGEAL DISORDERS:
• anatomical problems (hiatal hernia, esophageal stricture, esophageal web,
esophageal diverticulum, esophageal ring, tumors)
• inflammation (esophagitis) – due to GE reflux, medications (e.g., ASA, NSAIDs,
KCl, iron, vit C, TCN), chemicals (lye or acid)
• esophageal dysmotility - difficulty with movement of food, solid or liquid,
through the esophagus due to decreased or ineffectual peristalsis (e.g., presbyesophagus), diffuse spasm, achalasia
• may involve retrograde movement of material from the esophagus to the pharynx
GE REFLUX
• retrograde movement of gastric contents from the stomach into the esophagus and
higher, the latter possibly resulting in aspiration of contents into the trachea and lungs
• natural occurrence • symptomatic vs. asymptomatic
• degree of esophageal damage varies (most severe – Barrett’s)
• effects on pharynx, larynx, and tracheobronchial system • antireflux barrier:
• esophageal clearance (gravity, peristalsis, salivation, anchoring of distal
• gastric reservoir (dilatation, increased intragastric pressure, delayed gastric
Specific Clinical Risk Factors: GI Problems in People with Developmental Disabilities
Those at special risk:
ٱ Individuals with cerebral palsy, Down Syndrome (especially as they age)
ٱ Individuals with facial malformations (e.g., cleft palate) ٱ Individuals who have had strokes or problems resulting in paralysis of
ٱ Individuals with Bell’s palsy ٱ Individuals who have difficult to control seizure disorders ٱ Individuals with Parkinson’s Disease, neuromuscular disorders
ٱ Individuals with skeletal deformities such as severe (kypho)scoliosis ٱ Individuals with a collagen disease affecting the esophagus (scleroderma,
ٱ Premature infants ٱ Individuals who are marginally compromised and are put on new medications
that have adverse side effects (e.g., psychotropic drugs, anticholinergics, anticonvulsant medications, medications for spasticity, any medication causing lethargy, calcium channel blockers, theophylline)
ٱ Individuals who have (or have a history of) esophageal lesions or cancers ٱ Recumbent positioning ٱ Increased abdominal tone ٱ Constipation ٱ Individuals who steal food ٱ Individuals who eat too fast
Clinical Implications: Morbidity (illness) Recurrent respiratory infections, changes in pulmonary status Inadequate hydration, leading to problems with blood electrolytes, lethargy, worsening constipation Inadequate nutrition (malnutrition) leading to compromised health status Inability to take medications properly (e.g., seizure control) Esophageal changes (esophageal stricture, Barrett’s esophagus, esophageal cancer) Mortality (death)
Specific Clinical Risk Factors: GI Problems in People with Developmental Disabilities
What triggers the need for an investigation?
¾ It’s helpful when the individual can communicate verbally or otherwise. ¾ Sometimes the desire to please or fear can interfere. ¾ Sometimes there is a delay in recognition of the problem.
Signs & Symptoms:
Coughing, choking, cyanosis when eating or drinking Crying, tearing, irritability while eating or drinking Rales, stridor, wheezing, or congestion (“gurgling”) during or after eating or
Obvious difficulty chewing or swallowing Obvious discomfort, pain, fear, or distress while eating or drinking (e.g., feeling
Abnormal head/body positioning (especially backward arching at head/neck) Food/meal refusal (sometimes related to unfamiliar staff) Food spillage Fatigue with eating Recurrent emesis (may be behavioral but may be a symptom of GI discomfort or
Emesis during or after meals (including self-induced vomiting) Vomiting of blood or “coffee-ground” material Nasal reflux or regurgitation Excessive salivation or mucus production, difficulty handling secretions Rumination Recurrent respiratory infections/aspiration pneumonias Weight loss, chronic underweight status, or inadequate weight gain Persistent or recurrent dehydration Low grade fevers or spiking fevers of unknown cause Unexplained anemia (iron deficiency anemia when there has been sufficient blood
Chronic pharyngitis, laryngitis Behavior problems around mealtime Evidence of interstitial fibrosis on chest x-ray Decreased serum protein, albumin, prealbumin levels
Evaluation:
History and Physical exam Lab – CBC, chemistries, stool for blood, emesis for blood, x-rays Occupational or swallowing therapy assessment via history, exam, mealtime
History – previous x-rays, pulmonary pathology) Exam of oral structures, facial symmetry, muscle tone, dentition, tongue
movements, lip and jaw closure, method of processing food, drooling)
- pharyngeal structure, symmetry, delay, seepage, residue, timing and
Specific Clinical Risk Factors: GI Problems in People with Developmental Disabilities
- esophageal structure/abnormalities, motility/peristalsis
(primary/secondary/tertiary waves), lower esophageal esophageal sphincter relaxation/patency, GE reflux, hiatal hernia
Consultation with gastroenterologist who may elect to do:
- esophageal manometry (pressure measurements) - esophagogastroduodenoscopy (looking into the esophagus, stomach, and
duodenum, taking biopsies, looking for H. pylori)
Treatment: General Treatment: Avoid constipation. If it is a problem, treat it (adequate hydration, fiber, other dietary measures, medications, avoid medications that cause it or worsen it) Treatment for Dysphagia & Esophageal Dysmotility:
Diet texture changes, thickening of liquids Feeding techniques Thermal stimulation Physical management – positioning NG tube (short term when cause is self-limited or responsive to other treatment) G-tube
onths with an NG tube, documented aspiration or aspiration
ng times, failure of more conservative treatment,
esophageal obstruction or dysfunction (Note that GERD is not on this list)
emorrhage, malposition of tube, granulation
, gastrocolic or gastroenteric fistula, migration of the tube,
enlargement of the stoma, aspiration pneumonia
o contraindications: gastric outlet obstruction, severe intractable gastroparesis,
o benefits: convenient, easy to maintain and use, natural use of GI tract,
improved nutritional and hydration status, medication administration
G-tubes do not solve other GI problems such as GERD, aspiration of oral secretions, gastroparesis.
Specific Clinical Risk Factors: GI Problems in People with Developmental Disabilities
Treatment for GERD: Positioning measures: Elevate head of bed Avoiding predisposing factors: overeating, bedtime snacks, high fat foods, smoking,
alcohol, medications that make it worse, foods that make it worse (high-fat, peppermint, chocolate, high acid content, caffeine), tight clothing over the abdomen, posture that increase intraabdominal pressure
Medications:
- Antacids - H2 blockers (H2 receptor antagonists)–Tagamet, Zantac, Pepcid, Axid
side effects – rare – headache, lethargy, confusion, depression,
hallucinations, hepatitis, hematological toxicity
medication interaction – primarily with Tagamet – theophylline,
- Proton pump inhibitors – Prilosec, Prevacid, Aciphex, Nexium, Protonix
side effects – gynecomastia, myopathy, rashes, interstitial nephritis,
concern about bacterial overgrowth and gastric tumor with long-term use
medication interaction – Valium, Coumadin, Dilantin, Digoxin,
- Prokinetic agents - Reglan - Ulcer adherents - Carafate
Esophageal dilatation for stricture Surgical Intervention:
Suggested criteria: persistence or recurrence of symptoms or complications after
8-12 weeks of intensive acid suppression therapy, increased esophageal exposure to gastric acid evident on 24-hour pH monitoring, documentation of a mechanically defective LES on manometry
Factors to consider: strength of propulsive movements, anatomic shortening of
esophagus (e.g., hiatal hernia), symptoms suggestive of duodenogastric reflux, hypersecretion of gastric acid, delayed gastric emptying
Most common procedure: Nissen fundoplication (open vs. laparoscopic)
- Contraindications to laparoscopic repair: remedial repair, need for
other procedure that cannot be done by laparoscopy, incisional abdominal hernia that also needs repair
- Relative contraindications: obesity, large hiatal hernia
Important factors to remember when dealing with GI issues in the DD population:
¾ Be proactive – early detection, evaluation, and intervention ¾ Monitor the weight record, intervening early ¾ Provide education/inservicing of staff, especially about the physical/nutritional
Specific Clinical Risk Factors: GI Problems in People with Developmental Disabilities
at risk unattended during meal preparation or at
- Be consistent in following the individual’s PNMP - Don’t change diet texture without permission. - Maintain proper positioning at all times, in all situations - Report any concerns to nurse or supervisory person.
¾ Monitor the PNMP for consistency, effectiveness, need for modification, user-
friendliness (easy to put into place, keep clean), comfort, enhancement of feelings of security.
¾ Periodically review the medication regimen to see if any may be exacerbating the
A Comparison of 10 and 14 Days of Lansoprazole Triple Therapy for Eradication of Helicobacter pylori M. Brian Fennerty, MD; T. O. G. Kovacs, MD; R. Krause, MD; M. Haber, MD;A. Weissfeld, MD; N. Siepman, MD; P. Rose, MD Background: Data from large, multicenter, US studies in 84% (103/123) of those receiving 10-day triple therapydetermining the efficacy of triple therapy for the eradi-by
UniCare Updates HealthWave Managed Medicaid Formulary Changes do not apply to UniCare Commercial Formulary We would like to thank you for providing quality services to our UniCare HealthWave program members. This bulletin is to inform you that our Pharmacy and Therapeutics Committee recently reviewed several drug categories on the Formulary. The purpose of this letter is to notify yo